CG Oncology, Inc. Common stock (CGON)

Price$53.72

Value ScoreF

Growth ScoreA

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)11.88%

Price vs S&P 500 (4W)-22.83%

VGM Score56.15

Market Capitalization$4.74B

All Metrics

Book Value / Share (Quarterly)$12.41

P/TBV (Annual)4.45x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)176.56%

Cash Flow / Share (Quarterly)$-1.82

Price vs S&P 500 (YTD)21.23%

Net Profit Margin (TTM)-2865.69%

EPS (TTM)$-2.34

10-Day Avg Trading Volume0.99M

EPS Excl Extra (TTM)$-2.34

EPS (Annual)$-2.08

ROI (Annual)-21.31%

Gross Margin (Annual)-15.02%

Net Profit Margin (5Y Avg)-10844.39%

Cash / Share (Quarterly)$12.23

Revenue Growth QoQ (YoY)1982.69%

ROA (Last FY)-20.34%

Revenue Growth TTM (YoY)666.01%

EBITD / Share (TTM)$-2.68

ROE (5Y Avg)-23.98%

Operating Margin (TTM)-3277.82%

Cash Flow / Share (Annual)$-1.64

P/B Ratio4.34x

P/B Ratio (Quarterly)5.23x

Net Income / Employee (Annual)$-1,133,800

EV / Revenue (TTM)928.33x

Net Interest Coverage (TTM)-35442.00x

ROA (TTM)-22.24%

EPS Incl Extra (Annual)$-2.08

Current Ratio (Annual)24.63x

Quick Ratio (Quarterly)30.60x

3-Month Avg Trading Volume1.11M

52-Week Price Return101.73%

Revenue / Employee (TTM)$35,700

Tangible BV / Share (Quarterly)$12.40

P/S Ratio (Annual)1172.83x

Asset Turnover (Annual)0.01x

52-Week High$75.50

Operating Margin (5Y Avg)-12109.07%

EPS Excl Extra (Annual)$-2.08

26-Week Price Return19.80%

Quick Ratio (Annual)24.09x

13-Week Price Return-11.02%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)31.30x

Enterprise Value$4.71B

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$28,500

Pretax Margin (Annual)-3985.02%

Cash / Share (Annual)$9.20

3-Month Return Std Dev48.38%

Net Income / Employee (TTM)$-1,315,100

ROE (Last FY)-21.39%

EPS Basic Excl Extra (Annual)$-2.08

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.34

ROI (TTM)-23.26%

P/S Ratio (TTM)934.38x

Pretax Margin (5Y Avg)-10844.39%

Revenue / Share (Annual)$0.05

Tangible BV / Share (Annual)$9.32

Price vs S&P 500 (52W)77.36%

Year-to-Date Return29.38%

5-Day Price Return-9.30%

EPS Normalized (Annual)$-2.08

ROA (5Y Avg)-20.45%

Net Profit Margin (Annual)-3985.02%

Month-to-Date Return-13.76%

EBITD / Share (Annual)$-2.45

Operating Margin (Annual)-4722.13%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-21.56%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.34

P/TBV (Quarterly)5.24x

P/B Ratio (Annual)4.45x

Pretax Margin (TTM)-2865.69%

Book Value / Share (Annual)$9.33

Price vs S&P 500 (13W)-19.27%

Beta0.61x

Revenue / Share (TTM)$0.06

ROE (TTM)-23.33%

52-Week Low$23.65

vGradeF

gGradeA

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.71est. -0.59

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.19

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
CGONCG Oncology, Inc. Common stock	F	A	C	$53.72
AMGNAmgen Inc	C	C	C	$349.58
GILDGilead Sciences Inc	C	B	C	$129.16
ARGXargenx SE American Depositary Shares	D	A	B	$891.32
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$149.23
BIIBBiogen Inc. Common Stock	B	D	B	$195.34
BNTXBioNTech SE American Depositary Share	C	C	D	$88.08
MRNAModerna, Inc. Common Stock	C	B	B	$47.44
NBIXNeurocrine Biosciences Inc	C	B	B	$163.88
EXELExelixis Inc	C	B	B	$52.70
KRYSKrystal Biotech, Inc. Common Stock	D	B	A	$301.00

About

CG Oncology is a late-stage biopharmaceutical company developing cretostimogene grenadenorepvec, an intravesical oncolytic immunotherapy for non-muscle-invasive bladder cancer. The candidate is in two Phase 3 trials targeting BCG-unresponsive and intermediate-risk patients, along with a Phase 2 study combining the therapy with checkpoint inhibition. The treatment aims to offer a bladder-sparing alternative to surgery for qualifying patients.